| 2.59 -0.08 (-3%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.92 | 1-year : | 4.73 |
| Resists | First : | 3.36 | Second : | 4.05 |
| Pivot price | 2.64  |
|||
| Supports | First : | 2.24 | Second : | 1.86 |
| MAs | MA(5) : | 2.58  |
MA(20) : | 2.8 |
| MA(100) : | 3.35 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 35.1 |
D(3) : | 30.4 |
| RSI | RSI(14): 33.8 |
|||
| 52-week | High : | 4.94 | Low : | 1.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BDTX ] has closed above bottom band by 31.8%. Bollinger Bands are 68.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.65 - 2.66 | 2.66 - 2.67 |
| Low: | 2.5 - 2.52 | 2.52 - 2.53 |
| Close: | 2.57 - 2.59 | 2.59 - 2.61 |
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Thu, 04 Dec 2025
Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) - Finviz
Wed, 03 Dec 2025
Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire
Wed, 03 Dec 2025
Black Diamond (Nasdaq: BDTX) posts 86% CNS ORR, plans Phase 2 GBM trial - Stock Titan
Tue, 02 Dec 2025
Black Diamond Therapeutics to Host Webcast on Phase 2 Clinical Trial Results of Silevertinib on December 3, 2025 - Quiver Quantitative
Tue, 02 Dec 2025
Black Diamond Therapeutics to Host Webcast Presentation - GlobeNewswire
Thu, 20 Nov 2025
Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout (NASDAQ:BDTX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 79.5 (%) |
| Shares Short | 6,120 (K) |
| Shares Short P.Month | 6,170 (K) |
| EPS | 0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.21 |
| Profit Margin | 30.7 % |
| Operating Margin | 21.1 % |
| Return on Assets (ttm) | 6.2 % |
| Return on Equity (ttm) | 19.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.22 |
| Sales Per Share | 1.22 |
| EBITDA (p.s.) | 0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 21 (M) |
| Levered Free Cash Flow | 10 (M) |
| PE Ratio | 6.99 |
| PEG Ratio | 0 |
| Price to Book value | 1.17 |
| Price to Sales | 2.1 |
| Price to Cash Flow | 6.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|